Stock·NYSE·Healthcare
HCA Healthcare, Inc. (HCA)
- Market cap
- $104.97B
- P/E
- 15.69
- Dividend yield
- 0.65%
- Street target
- $476.00median of 26 analysts
- 52-week range
- $353.99 $556.52
HCA stock forecast today
Where HCA stands today, and what CleaRank Financial AI makes of it.
HCA at a glance
HCA Healthcare, Inc. (HCA): Buy, 77/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($437.41 and $444.39).
- Earnings HCA beat estimates in 7 of the 7 reports in our data, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $38.5M and made no open-market purchases over the last 18 months.
- Valuation P/E of 15.7 against 31.9 for the Healthcare sector: a discount to peers (-51%).
Figures as of October 30, 2026.
CleaRank Financial AI
CleaRank rates HCA Healthcare, Inc. (HCA) Buy, with a model score of 77/100.
The trend lifts the score most: the price is 6.48% above its 200-day average and 8.18% above its 50-day average. The 50-day average stands at $437.41 and the 200-day at $444.39. Over the past year the price rose 1.37%.
Only on CleaRank
Figures we compute ourselves from HCA's own price, earnings and insider-filing history. Tap one to see it in context.
HCA stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $473.19 is 8.2% above the 50-day simple moving average of $437.41.Price above its 200-day average ›
The price is 6.5% above the 200-day simple moving average of $444.39.50-day average below the 200-day ›
The 50-day average ($437.41) is 1.6% below the 200-day average ($444.39), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 59% of its 52-week range, between $353.99 and $556.52.
HCA share price
Pick a period: each tab shows how far HCA has moved over it, to the last close.
Today's trading
Where HCA sits inside today's range and its 52-week range.
HCA fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 15.69 is 50.8% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 1.33 is 60.8% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $6.8B on revenue of $78.7B, a net margin of 8.6%.Beat estimates in most recent reports ›
HCA beat the EPS estimate in 7 of the 7 reports in our data.Pays a dividend ›
The trailing dividend yield is 0.65%, or $3.06 a share a year.
Key statistics
The headline figures for HCA.
As of October 30, 2026, HCA trades at $473.19, with a market value of $104.97B, a P/E ratio of 15.69 and a dividend yield of 0.65%.
What the numbers say
CleaRank Financial AI's reading of HCA's valuation, growth and risks.
HCA Healthcare, Inc. (HCA) has a trailing P/E of 15.69, which is 50.8% below the Healthcare sector median of 31.9. The peer comparison on this page rates the P/E as a discount to peers. Its market capitalisation is $105.0B.
The business converts sales into profit at a net margin of 8.61% and an operating margin of 14.83%. The balance sheet and payout round out the picture, with a trailing dividend yield of 0.65% ($3.06 a share a year).
HCA reported EPS of $7.22 for the October 27, 2026 report, against an analyst estimate of $6.63, beating the estimate by 8.90%. The share price rose 2.95% in the following session, so the market responded positively.
HCA has beaten the EPS estimate in all 7 reports in our data; even so, 1 of those 7 beats was followed by a lower share price the next session. Analysts' average EPS estimate for this fiscal year is $29.49, which would be growth of 4.5%, and $31.99 for next year (growth of 8.5%).
HCA's average daily move is 1.75%, and its beta against the S&P 500 is 1.11. Over the last 18 months insiders sold $38.5M of stock and made no open-market purchases. Insider sales are often planned in advance or made to cover tax on vesting shares, so they tell less than purchases would.
HCA against the Healthcare sector
How HCA compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: HCA trades at a notable discount to sector peers (-51%), which may indicate undervaluation or specific company headwinds.
Return vs XLV: Since May 20, 2025, HCA has gained 22.6% against a gain of 37.3% for XLV.
Performance against XLV
HCA and the Healthcare sector fund over the same days.
Revenue and earnings
How much HCA sells, and how much of it becomes profit.
The quarterly bars end with Q2 '26 (the quarter to June 30, 2026); HCA reported again on October 27, 2026, and that quarter is not in our statement data yet. The 12-month figures come from the statistics feed and may include it.
Revenue growth: Revenue grew 7.1% in FY2025 to $75.6B, from $70.6B a year earlier.
Profit margin: The net margin was 10.3% in FY2025, up from 9.4% the year before.
Profitable: HCA earned $7.8B in FY2025.
Earnings reality check
Did HCA beat what analysts expected, and how did the stock react?
Earnings record: HCA beat the analyst estimate in 7 of the 7 reports in our data.
Market reaction: The stock fell in the first session after 1 of those 7 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 27, 2026after close | $6.63 | $7.22 | +8.90% | +2.95% | - |
| Jul 24, 2026after close | $7.50 | $7.59 | +1.20% | +1.94% | +5.34% |
| Apr 24, 2026after close | $7.13 | $7.15 | +0.28% | +3.08% | +0.15% |
| Jan 27, 2026after close | $7.48 | $8.01 | +7.09% | -2.89% | -1.31% |
| Jul 25, 2025after close | $6.32 | $6.84 | +8.23% | +1.86% | +6.77% |
| Apr 25, 2025after close | $5.75 | $6.45 | +12.17% | +1.25% | +6.11% |
| Jan 24, 2025after close | $6.14 | $6.22 | +1.30% | +6.05% | +5.38% |
As of October 30, 2026, HCA has beaten the analyst EPS estimate in 7 of the 7 reports in our data and fell in the first trading session after 1 of those beats; its latest report, on October 27, 2026, came in 8.90% above the estimate and the stock moved +2.95% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
HCA AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 60.7, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 60.7 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of HCA
The score, the reasoning behind it, and what could move the price next.
HCA Healthcare, Inc. (HCA) keeps an upward trend, priced at $473.19: 8.18% above its 50-day average of $437.41 and 6.48% above its 200-day average of $444.39. The 50-day average sits 1.57% below the 200-day, which shows the recovery has not reached the longer-run averages. Within its 52-week range of $353.99 to $556.52, the price sits at 59%, 14.97% below the high.
The 14-day RSI of 60.7 is in the bullish zone, below the overbought line, and the MACD line is positive. The recent returns are all positive: the price rose 17.54% over the past three months, rose 9.26% over the past six months and rose 1.37% over the past year.
Earnings beat ›
The October 27, 2026 report beat the EPS estimate by 8.90%, and the share price rose 2.95% in the first session after it.
Source: Earnings report, October 27, 2026New analyst coverage ›
BMO Capital started coverage at Outperform on September 23, 2026.
Source: Analyst action, BMO Capital, September 23, 2026Rating reaffirmed ›
TD Cowen kept its Buy rating on October 12, 2026.
Source: Analyst action, TD Cowen, October 12, 2026
- Keep an eye on the two closest levels. The 52-week high at $556.52 sits above the price, and the 20-day EMA at $457.86 sits below it.
- With the 14-day RSI at 60.7 (bullish zone) and the MACD line positive, momentum looks constructive. Readings above 70 or below 30 would signal stretched momentum.
- After the October 27, 2026 report the share price rose 2.95% in the first session; HCA beat estimates in 7 of the 7 reports in our data.
HCA's uptrend depends on the price holding above its 50-day average at $437.41 and its 200-day average at $444.39. A close below the 200-day would be the first sign of that trend cracking. If the price pulls back, the first level it would reach is the 20-day EMA at $457.86.
The next level overhead is the 52-week high at $556.52. The RSI sits in the bullish zone, which suggests momentum still supports the move.
Technical indicators
Momentum and trend for HCA, from its daily closes.
As of October 30, 2026, with HCA at $473.19, its 14-day RSI is 60.7 (showing bullish momentum without being overbought), its 50-day simple moving average is $437.41 and its 200-day is $444.39.
Calculated by CleaRank on daily closes as of October 30, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What HCA moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 30, 2026, HCA's 1-year correlation of daily returns is +0.14 with S&P 500 (SPY), +0.03 with Nasdaq 100 (QQQ), -0.02 with Bitcoin (BTC) and +0.01 with gold (XAU).
HCA price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
15 of 26 analysts rate it a buy or strong buy, 9 a hold and 2 a sell.Median target above the price ›
The median 12-month target of $476.00 is 0.6% above the price.More buy ratings than three months ago ›
15 of 26 rate it a buy now, against 14 of 25 three months ago.
HCA Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 12, 2026 | TD Cowen | Maintains | Buy |
| Oct 7, 2026 | RBC Capital | Maintains | Outperform |
| Sep 23, 2026 | BMO Capital | Initiates | Outperform |
| Sep 18, 2026 | Leerink Partners | Maintains | Outperform |
| Sep 8, 2026 | RBC Capital | Reiterates | Outperform |
| Aug 20, 2026 | JP Morgan | Maintains | Neutral |
As of October 30, 2026, 26 Wall Street analysts cover HCA: 15 rate it a buy or strong buy, 9 a hold and 2 a sell or strong sell. Their 12-month price targets range from $380.00 to $579.00. The median HCA price target is $476.00, 0.6% above the price of $473.19.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
HCA trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
HCA trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from HCA's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much HCA tends to move, against the market and on its own.
HCA price history and drawdowns
HCA's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
4/4Average daily move under 2% ›
The price has moved 1.75% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 44.5%, from February 2020 to March 2020, regained by November 2020.Most 1-year holds ended higher ›
82% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $66,859, against $41,607 in the S&P 500 (SPY).
HCA Drawdowns & Recovery
As of October 30, 2026, HCA's worst peak-to-trough fall over the last 10 years with dividends reinvested was -44.5% (February 2020 to March 2020); it regained that peak by November 2020, 8 months after the low, and 82% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into HCA in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: HCA beat the S&P 500 over this period: $66,859 against $41,607.
A $10,000 investment in HCA in October 2016 would be worth about $66,859 today with dividends reinvested, compared with about $41,607 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to HCA, and which have not.
Strongest month, July: an average of +6.00%, up in 5 of 10 years.
Weakest month, March: an average of -2.12%, up in 6 of 10 years.
This month, October: has averaged -0.04%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, HCA's strongest calendar month has been July (average +6.00%, up in 5 of 10 years) and its weakest March (average -2.12%, up in 6 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
HCA stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in HCA, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in HCA today could grow to about $14,769 by 2030 in the base case, with a 90th-percentile outcome near $34,580 and a 10th-percentile outcome around $6,308. The simulation models price only; at today's 0.65% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
HCA Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $699 for HCA by 2030 in the base case, from $473 today (1.5x over 4 years). The 10th-percentile path ends near $298. These are outcomes of a Monte Carlo simulation run on HCA's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $341 | $522 | $798 | |
| 2028 | $315 | $575 | $1,049 | |
| 2029 | $303 | $634 | $1,324 | |
| 2030 | $298 | $699 | $1,636 |
Method: a lognormal simulation of HCA's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
HCA insider trading
What the people running the company have bought and sold.
HCA insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought HCA shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 30, 2026, HCA insiders reported 8 open-market sales worth $38.5M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 7, 2026 | Mike A Marks
Chief Financial Officer
|
Grant | 3.3K | - |
| Apr 28, 2026 | John W Chidsey
Director
|
Grant | 809 | - |
| Apr 28, 2026 | Nancy-Ann M. Deparle, J.D.
Director
|
Grant | 509 | - |
| Apr 28, 2026 | Thomas F Frist III
Director and Beneficial Owner of more than 10% of a Class of Security
|
Grant | 1.0K | - |
| Apr 28, 2026 | William R. Frist
Director and Beneficial Owner of more than 10% of a Class of Security
|
Grant | 809 | - |
| Apr 28, 2026 | Hugh F. Johnston
Director
|
Grant | 809 | - |
| Apr 28, 2026 | Michael W Michelson
Director
|
Grant | 925 | - |
| Apr 28, 2026 | Wayne Joseph Riley
Director
|
Grant | 509 | - |
| Apr 28, 2026 | Andrea B Smith
Director
|
Grant | 509 | - |
| Feb 18, 2026 | Michael R. Mcalevey
Officer
|
Sell | 1.7K | $903.5K |
| Feb 13, 2026 | Michael R. Mcalevey
Officer
|
Option | 5.0K | $1.2M |
| Feb 11, 2026 | Jennifer Berres
Officer
|
Sell | 8.0K | $4.1M |
| Feb 11, 2026 | Christopher F Wyatt
Officer
|
Sell | 4.0K | $2.0M |
| Feb 10, 2026 | Jennifer Berres
Officer
|
Grant | 7.1K | - |
| Feb 10, 2026 | Michael S Cuffe
Officer
|
Grant | 9.6K | - |
| Feb 10, 2026 | Jon Mark Foster
Chief Operating Officer
|
Grant | 15.7K | - |
| Feb 10, 2026 | Samuel N Hazen
Chief Executive Officer
|
Grant | 54.9K | - |
| Feb 10, 2026 | Mike A Marks
Chief Financial Officer
|
Grant | 5.0K | - |
| Feb 10, 2026 | Michael R. Mcalevey
Officer
|
Grant | 8.4K | - |
| Feb 10, 2026 | Erica Rossitto
Officer
|
Grant | 1.7K | - |
| Feb 10, 2026 | Christopher F Wyatt
Officer
|
Grant | 3.4K | - |
| Feb 5, 2026 | Jon Mark Foster
Chief Operating Officer
|
Option | 29.3K | $4.1M |
| Feb 5, 2026 | Christopher F Wyatt
Officer
|
Option | 10.7K | $1.5M |
| Feb 3, 2026 | Samuel N Hazen
Chief Executive Officer
|
Sell | 42.9K | $21.5M |
| Feb 3, 2026 | Michael S Cuffe
Officer
|
Sell | 1.5K | $747.1K |
| Feb 3, 2026 | Michael S Cuffe
Officer
|
Grant | 4.1K | - |
| Jan 30, 2026 | Samuel N Hazen
Chief Executive Officer
|
Option | 84.4K | $6.9M |
| Nov 14, 2025 | Samuel N Hazen
Chief Executive Officer
|
Grant | 14.8K | - |
| Nov 5, 2025 | Michael R. Mcalevey
Officer
|
Sell | 3.9K | $1.8M |
| Nov 5, 2025 | Mike A Marks
Chief Financial Officer
|
Grant | 330 | - |
| Nov 3, 2025 | Michael R. Mcalevey
Officer
|
Option | 13.2K | $3.1M |
| Oct 31, 2025 | Samuel N Hazen
Chief Executive Officer
|
Option | 58.1K | $4.0M |
| Sep 8, 2025 | Michael S Cuffe
Officer
|
Sell | 3.8K | $1.6M |
| Sep 4, 2025 | Michael S Cuffe
Officer
|
Option | 10.9K | $1.9M |
| Jul 29, 2025 | John W Chidsey
Director
|
Grant | 496 | - |
| May 13, 2025 | Jon Mark Foster
Officer
|
Sell | 15.7K | $5.8M |
| May 13, 2025 | Jon Mark Foster
Officer
|
Grant | 3.2K | - |
| May 13, 2025 | Samuel N Hazen
Chief Executive Officer
|
Grant | 90.1K | - |
| May 7, 2025 | Mike A Marks
Chief Financial Officer
|
Grant | 935 | - |
Source: TwelveData, from SEC Form 4 filings
HCA stock forecast: questions people ask
Answered from the figures on this page, as of October 30, 2026.